General Information of This Target (ID: PATR0DYRGS)
Target Name
Eukaryotic elongation factor 2 kinase (EEF2K)
Gene Name
EEF2K
Gene ID
29904
Synonym
Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase
Sequence
MADEDLIFRLEGVDGGQSPRAGHDGDSDGDSDDEEGYFICPITDDPSSNQNVNSKVNKYY
SNLTKSERYSSSGSPANSFHFKEAWKHAIQKAKHMPDPWAEFHLEDIATERATRHRYNAV
TGEWLDDEVLIKMASQPFGRGAMRECFRTKKLSNFLHAQQWKGASNYVAKRYIEPVDRDV
YFEDVRLQMEAKLWGEEYNRHKPPKQVDIMQMCIIELKDRPGKPLFHLEHYIEGKYIKYN
SNSGFVRDDNIRLTPQAFSHFTFERSGHQLIVVDIQGVGDLYTDPQIHTETGTDFGDGNL
GVRGMALFFYSHACNRICESMGLAPFDLSPRERDAVNQNTKLLQSAKTILRGTEEKCGSP
QVRTLSGSRPPLLRPLSENSGDENMSDVTFDSLPSSPSSATPHSQKLDHLHWPVFSDLDN
MASRDHDHLDNHRESENSGDSGYPSEKRGELDDPEPREHGHSYSNRKYESDEDSLGSSGR
VCVEKWNLLNSSRLHLPRASAVALEVQRLNALDLEKKIGKSILGKVHLAMVRYHEGGRFC
EKGEEWDQESAVFHLEHAANLGELEAIVGLGLMYSQLPHHILADVSLKETEENKTKGFDY
LLKAAEAGDRQSMILVARAFDSGQNLSPDRCQDWLEALHWYNTALEMTDCDEGGEYDGMQ
DEPRYMMLAREAEMLFTGGYGLEKDPQRSGDLYTQAAEAAMEAMKGRLANQYYQKAEEAW
AQMEE

    Click to Show/Hide
Family
the protein kinase superfamily, Alpha-type
Function
Threonine kinase that regulates protein synthesis by controlling the rate of peptide chain elongation. Upon activation by a variety of upstream kinases including AMPK or TRPM7, phosphorylates the elongation factor EEF2 at a single site, renders it unable to bind ribosomes and thus inactive. In turn, the rate of protein synthesis is reduced.

    Click to Show/Hide
Uniprot Entry
EF2K_HUMAN
HGNC ID
HGNC:24615
KEGG ID
hsa:29904
Full List of The ADC Related to This Target
Investigative
Click To Hide/Show 43 ADC Related to This Stage
ADC Name Antibody Antigen Payload Linker ADC Info
A43-PE24 [1]
Anti-GPC3 mAb A43
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
HN3-PE24 [1]
Anti-GPC3 mAb HN3
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
C46-PE24 [1]
Anti-GPC3 mAb C46
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
J80A-PE24 [1]
Anti-GPC3 mAb J80A
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
H8R23-DT3C [2]
Anti-ANTXR2 mAb H8R23
Anthrax toxin receptor 2 (ANTXR2)
Diphtheria toxin containing streptococcal protein G (DT3C)
Undisclosed
A5-PE24 [1]
Anti-GPC3 mAb A5
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
J80B-PE24 [1]
Anti-GPC3 mAb J80B
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
I82-PE24 [1]
Anti-GPC3 mAb I82
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
A18-PE24 [1]
Anti-GPC3 mAb A18
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
H49-PE24 [1]
Anti-GPC3 mAb H49
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
G15-PE24 [1]
Anti-GPC3 mAb G15
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
F5-PE24 [1]
Anti-GPC3 mAb F5
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
J58-PE24 [1]
Anti-GPC3 mAb J58
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
F67-PE24 [1]
Anti-GPC3 mAb F67
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
I34-PE24 [1]
Anti-GPC3 mAb I34
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
I88-PE24 [1]
Anti-GPC3 mAb I88
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
R6-PE24 [1]
Anti-GPC3 mAb R6
Glypican-3 (GPC3)
Pseudomonas exotoxin PE24
Undisclosed
DVHH6-PE38 [3]
Humanized CD7 nanobody Dvhh6
T-cell antigen CD7 (CD7)
Pseudomonas exotoxin PE38
Undisclosed
Anti-Tac (Fv)-PE38KDEL conjugate [4]
Anti-Tac (Fv)
Interleukin-1 receptor type 2 (IL1R2)
Pseudomonas exotoxin PE38
Undisclosed
LMB-75 [5]
Undisclosed
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
Pseudomonas exotoxin PE24
Undisclosed
LMB-70 [6]
Undisclosed
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
Pseudomonas exotoxin PE24
Undisclosed
VGRNb-DT [7]
Anti-VEGFR-2 nanobody
Vascular endothelial growth factor receptor 2 (KDR)
Diphtheria toxin
Sulfo-SMCC
DT390 anti-CD3sFv immunotoxin [8]
Anti-CD3 single-chain Fv
Myeloid cell surface antigen CD33 (CD33)
DT390
Undisclosed
Labetuzumab-PE40 conjugate [9]
Labetuzumab
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Pseudomonas exotoxin PE40
Undisclosed
GD17-PE40 [10]
GD17 mAb
Endoplasmic reticulum chaperone BiP (HSPA5)
Pseudomonas exotoxin PE40
Undisclosed
G28-5 sFv-PE40 [11]
Anti-human CD40 MoAb G28-5
Tumor necrosis factor receptor superfamily member 5 (CD40)
Pseudomonas exotoxin PE40
Undisclosed
DVHH6-PE-LR [3]
Humanized CD7 nanobody Dvhh6
T-cell antigen CD7 (CD7)
Pseudomonas exotoxin PE38 with protease-resistant (PE-LR)
Undisclosed
DhuVHH6-PE-LR [3]
dhuVHH6
T-cell antigen CD7 (CD7)
Pseudomonas exotoxin PE38 with protease-resistant (PE-LR)
Undisclosed
HSL156 mAb-DT3C conjugate [12]
HSL156
Junctional adhesion molecule C (JAM3)
Diphtheria toxin containing streptococcal protein G (DT3C)
Undisclosed
scFv (Herceptin)-PE [13]
Trastuzumab scFv
Receptor tyrosine-protein kinase erbB-2 (HER2)
Pseudomonas exotoxin PE38
Undisclosed
scFv(Herceptin)-PE-STXA [13]
Trastuzumab scFv
Receptor tyrosine-protein kinase erbB-2 (HER2)
PE15-Stx 2a
Undisclosed
ScFv(trastuzumab)-PE38KDEL [14]
Trastuzumab scFv
Receptor tyrosine-protein kinase erbB-2 (HER2)
Pseudomonas exotoxin PE38
Undisclosed
ScFv(H32)-PE38KDEL [14]
Anti-HER2 IgG1(H32) scFv
Receptor tyrosine-protein kinase erbB-2 (HER2)
Pseudomonas exotoxin PE38
Undisclosed
ScFv(GH2-20)-PE38KDEL [14]
Anti-HER2 IgG1(GH2-20) scFv
Receptor tyrosine-protein kinase erbB-2 (HER2)
Pseudomonas exotoxin PE38
Undisclosed
ScFv(GH2-61)-PE38KDEL [14]
Anti-HER2 IgG1(GH2-61) scFv
Receptor tyrosine-protein kinase erbB-2 (HER2)
Pseudomonas exotoxin PE38
Undisclosed
ScFv(GH2-75)-PE38KDEL [14]
Anti-HER2 IgG1(GH2-75) scFv
Receptor tyrosine-protein kinase erbB-2 (HER2)
Pseudomonas exotoxin PE38
Undisclosed
LMB-100 [15]
Anti-MSLN scFv
Mesothelin (MSLN)
Pseudomonas exotoxin LO10R456A
Undisclosed
LMB-12 [15]
Anti-MSLN scFv
Mesothelin (MSLN)
Pseudomonas exotoxin PE24
Undisclosed
LMB-164 [15]
Anti-MSLN scFv
Mesothelin (MSLN)
Pseudomonas exotoxin PE24
Undisclosed
HD7-1 (VL-VH)-PE40 [16]
Anti-PSMA mAb hD7-1
Glutamate carboxypeptidase 2 (FOLH1)
Pseudomonas exotoxin PE40
Undisclosed
HD7-1 (VL-VH)-PE24 [16]
Anti-PSMA mAb hD7-1
Glutamate carboxypeptidase 2 (FOLH1)
Pseudomonas exotoxin PE24
Undisclosed
HD7-1 (VL-VH)-PE24mut [16]
Anti-PSMA mAb hD7-1
Glutamate carboxypeptidase 2 (FOLH1)
Pseudomonas exotoxin PE24 mut
Undisclosed
RG7787 [17]
Anti-MSLN Anti-ody Fab fragment
Mesothelin (MSLN)
Pseudomonas exotoxin PE24
Undisclosed
Investigative(Terminated)
Click To Hide/Show 2 ADC Related to This Stage
ADC Name Antibody Antigen Payload Linker ADC Info
Monoclonal antibody B3-Lys-PE40 conjugate [18]
Murine mAb B3
Poly [ADP-ribose] polymerase 1 (PARP1)
LysPE40
Undisclosed
Monoclonal antibody C242-PE conjugate [19]
Anti-CD138 mAb C242
Mucin-1 (MUC1)
Pseudomonas exotoxin PE40
Undisclosed
References
Ref 1 Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma. J Cancer. 2022 Feb 14;13(4):1370-1384.
Ref 2 Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations. Exp Cell Res. 2022 Apr 15;413(2):113078.
Ref 3 Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomedicine. 2017 Mar 13;12:1969-1983. doi: 10.2147/IJN.S127575. eCollection 2017.
Ref 4 Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood. 1994 Jan 15;83(2):426-34.
Ref 5 Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4592-4598. doi: 10.1073/pnas.1821733116. Epub 2019 Feb 19.
Ref 6 Targeted Therapy With Immunoconjugates for Multiple Myeloma. Front Immunol. 2020 Jun 19;11:1155. doi: 10.3389/fimmu.2020.01155. eCollection 2020.
Ref 7 Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line. Mol Biotechnol. 2022 Nov;64(11):1218-1226. doi: 10.1007/s12033-022-00485-1. Epub 2022 Apr 27.
Ref 8 Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor. Blood. 1996 Sep 15;88(6):2342-53.
Ref 9 Introduction to basic information on ADC drug Labetuzumab-PE40 conjugate; 27 Oct 2020.
Ref 10 A new therapeutic application using GRP78-specific single-chain antibody fragment (scFv) fused immnunotoxin. Cancer Res (2009) 69 (9_Supplement): 3236.
Ref 11 In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood. 1997 Jun 15;89(12):4493-500.
Ref 12 Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma. Exp Cell Res. 2023 May 15;426(2):113570. doi: 10.1016/j.yexcr.2023.113570. Epub 2023 Mar 27.
Ref 13 Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins. J Steroid Biochem Mol Biol. 2020 Jun;200:105651. doi: 10.1016/j.jsbmb.2020.105651. Epub 2020 Mar 5.
Ref 14 Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. MAbs. 2019 Jan;11(1):153-165. doi: 10.1080/19420862.2018.1541370. Epub 2018 Nov 8.
Ref 15 Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2.
Ref 16 In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer. Anticancer Res. 2018 Jan;38(1):61-69. doi: 10.21873/anticanres.12192.
Ref 17 Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Res. 2016 Mar 15;76(6):1560-8. doi: 10.1158/0008-5472.CAN-15-2401. Epub 2015 Dec 30.
Ref 18 Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3358-62. doi: 10.1073/pnas.88.8.3358.
Ref 19 Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. J Clin Invest. 1992 Aug;90(2):405-11. doi: 10.1172/JCI115875.